mProX™ Human CD27 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD27 is a cell surface protein that has various applications in different fields. In the context of regulatory T cells (Treg), CD27 has been found to be co-expressed with the activation/memory marker HLA-DR. This subset of Treg, known as HLA-DR+CD27+ DP-Enriched Xn-Treg, exhibits enhanced antigen-specific suppressive function and has potential for the treatment of autoimmune diseases and graft rejection. CD27 has also been studied in the context of osteosarcoma, where it is implicated in influencing the prognostic and immune microenvironment of the disease. Additionally, CD27 is a therapeutic target for the treatment of various types of tumors, including lymphoma, renal cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and ovarian cancer. Antibodies targeting CD27, such as IMM40H, have been developed and shown to eliminate tumors through Fc-mediated effector functions and interrupt CD70/CD27 signaling. Furthermore, CD27 is involved in chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, where fifth-generation CAR-T cells targeting B cell maturation antigen (BCMA) and incorporating CD27 signaling have been found to enhance antitumor efficacy, proliferative capacity, and alleviate T cell exhaustion. Overall, CD27 plays a significant role in immunological responses and has potential applications in the treatment of autoimmune diseases, cancer, and infectious diseases such as COVID-19.